Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Breast Cancer | Research

Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers

Authors: Yiduo Liu, Linxin Teng, Shiyi Fu, Guiyang Wang, Zhengjun Li, Chao Ding, Haodi Wang, Lei Bi

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Triple-negative breast cancer (TNBC) is a highly heterogeneous subtype of breast cancer, showing aggressive clinical behaviors and poor outcomes. It urgently needs new therapeutic strategies to improve the prognosis of TNBC. Bioinformatics analyses have been widely used to identify potential biomarkers for facilitating TNBC diagnosis and management.

Methods

We identified potential biomarkers and analyzed their diagnostic and prognostic values using bioinformatics approaches. Including differential expression gene (DEG) analysis, Receiver Operating Characteristic (ROC) curve analysis, functional enrichment analysis, Protein-Protein Interaction (PPI) network construction, survival analysis, multivariate Cox regression analysis, and Non-negative Matrix Factorization (NMF).

Results

A total of 105 DEGs were identified between TNBC and other breast cancer subtypes, which were regarded as heterogeneous-related genes. Subsequently, the KEGG enrichment analysis showed that these genes were significantly enriched in ‘cell cycle’ and ‘oocyte meiosis’ related pathways. Four (FAM83B, KITLG, CFD and RBM24) of 105 genes were identified as prognostic signatures in the disease-free interval (DFI) of TNBC patients, as for progression-free interval (PFI), five genes (FAM83B, EXO1, S100B, TYMS and CFD) were obtained. Time-dependent ROC analysis indicated that the multivariate Cox regression models, which were constructed based on these genes, had great predictive performances. Finally, the survival analysis of TNBC subtypes (mesenchymal stem-like [MSL] and mesenchymal [MES]) suggested that FAM83B significantly affected the prognosis of patients.

Conclusions

The multivariate Cox regression models constructed from four heterogeneous-related genes (FAM83B, KITLG, RBM24 and S100B) showed great prediction performance for TNBC patients’ prognostic. Moreover, FAM83B was an important prognostic feature in several TNBC subtypes (MSL and MES). Our findings provided new biomarkers to facilitate the targeted therapies of TNBC and TNBC subtypes.

Available only for authorised users

de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat. 2010;119(1):119–26. https://doi.org/10.1007/s10549-009-0499-6.CrossRefPubMed

Lee A, Moon BI, Kim TH. BRCA1/BRCA2 pathogenic variant breast Cancer: treatment and prevention strategies. Ann Lab Med. 2020;40(2):114–21. https://doi.org/10.3343/alm.2020.40.2.114.CrossRefPubMed

Fan M, Chen J, Gao J, Xue W, Wang Y, Li W, et al. Triggering a switch from basal- to luminal-like breast cancer subtype by the small-molecule diptoindonesin G via induction of GABARAPL1. Cell Death Dis. 2020;11(8):635. https://doi.org/10.1038/s41419-020-02878-z.CrossRefPubMedPubMedCentral

Vagia E, Mahalingam D, Cristofanilli M: The Landscape of Targeted Therapies in TNBC. Cancers 2020;12(4):916.

Chuan T, Li T, Yi C. Identification of CXCR4 and CXCL10 as potential predictive biomarkers in triple negative breast Cancer (TNBC). Med Sci Monitor. 2020;26:e918281.CrossRef

Rigiracciolo DC, Nohata N, Lappano R, Cirillo F, Talia M, Scordamaglia D, Gutkind JS, Maggiolini M: IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells. Cells 2020;9(4):1010.

De-la-Cruz-Ku G, Luyo M, Morante Z, Enriquez D, Möller MG, Chambergo-Michilot D, et al. Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience. PLoS One. 2020;15(8):e0237811. https://doi.org/10.1371/journal.pone.0237811.CrossRefPubMedPubMedCentral

Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's surveillance, epidemiology, and end results database. Cancer. 2007;110(4):876–84. https://doi.org/10.1002/cncr.22836.CrossRefPubMed

Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast Cancer molecular subtypes: implications for Neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. https://doi.org/10.1371/journal.pone.0157368.CrossRefPubMedPubMedCentral

10.

Li HY, Liang JL, Kuo YL, Lee HH, Calkins MJ, Chang HT, et al. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Res. 2017;19(1):133. https://doi.org/10.1186/s13058-017-0918-2.CrossRefPubMedPubMedCentral

11.

Ryan D, Paul BT, Koziol J, ElShamy WM. The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells. Breast Cancer Res. 2019;21(1):53. https://doi.org/10.1186/s13058-019-1131-2.CrossRefPubMedPubMedCentral

12.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81. https://doi.org/10.1200/JCO.2007.14.4147.CrossRefPubMed

13.

Tan DS, Marchió C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS: Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008, 111(1):27–44, 1, DOI: https://doi.org/10.1007/s10549-007-9756-8.

14.

Rastelli F, Biancanelli S, Falzetta A, Martignetti A, Casi C, Bascioni R, et al. Triple-negative breast cancer: current state of the art. Tumori. 2010;96(6):875–88. https://doi.org/10.1177/548.6505.CrossRefPubMed

15.

Chen J, Zhu M, Zou L, Xia J, Huang J, Deng Q, et al. Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO. Acta Biochim Biophys Sin. 2020;52(8):801–9. https://doi.org/10.1093/abbs/gmaa072.CrossRefPubMed

16.

Mir M, Khan H, Mehraj U, Nisar S, Bhat B, Wani N. Targeting different pathways using novel combination therapy in triple negative breast Cancer. Curr Cancer Drug Targets. 2020;20(8):586–602. https://doi.org/10.2174/1570163817666200518081955.CrossRefPubMed

17.

Sharma P. Biology and Management of Patients with Triple-Negative Breast Cancer. Oncologist. 2016;21(9):1050–62. https://doi.org/10.1634/theoncologist.2016-0067.CrossRefPubMedPubMedCentral

18.

Xiong G, Stewart RL, Chen J, Gao T, Scott TL, Samayoa LM, et al. Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance. Nat Commun. 2018;9(1):4456. https://doi.org/10.1038/s41467-018-06893-9.CrossRefPubMedPubMedCentral

19.

O'Reilly EA, Gubbins L, Sharma S, Tully R, Guang MH, Weiner-Gorzel K, et al. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin. 2015;3:257–75. https://doi.org/10.1016/j.bbacli.2015.03.003.CrossRefPubMedPubMedCentral

20.

Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic markers in triple-negative breast Cancer. Clin Breast Cancer. 2018;18(5):e841–50. https://doi.org/10.1016/j.clbc.2018.07.023.CrossRefPubMed

21.

Polyak K, Metzger Filho O. SnapShot: breast cancer. Cancer Cell. 2012;22(4):562–562.e561.CrossRef

22.

Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba, II, Tripathy D, Bernatchez C et al: Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers 2019;11(5):714.

23.

Li S, Yang R, Sun X, Miao S, Lu T, Wang Y, et al. Identification of SPP1 as a promising biomarker to predict clinical outcome of lung adenocarcinoma individuals. Gene. 2018;679:398–404. https://doi.org/10.1016/j.gene.2018.09.030.CrossRefPubMed

24.

Corces MR, Granja JM, Shams S, Louie BH, Seoane JA, Zhou W, Silva TC, Groeneveld C, Wong CK, Cho SW et al: The chromatin accessibility landscape of primary human cancers. Science (New York, NY) 2018;362(6413):eaav1898.

25.

Xu M, Li Y, Li W, Zhao Q, Zhang Q, Le K, et al. Immune and Stroma related genes in breast Cancer: a comprehensive analysis of tumor microenvironment based on the Cancer genome atlas (TCGA) database. Front Med. 2020;7:64. https://doi.org/10.3389/fmed.2020.00064.CrossRef

26.

Li MX, Jin LT, Wang TJ, Feng YJ, Pan CP, Zhao DM, et al. Identification of potential core genes in triple negative breast cancer using bioinformatics analysis. OncoTargets Ther. 2018;11:4105–12. https://doi.org/10.2147/OTT.S166567.CrossRef

27.

Liu X, Wu J, Zhang D, Bing Z, Tian J, Ni M, et al. Identification of potential key genes associated with the pathogenesis and prognosis of gastric Cancer based on integrated bioinformatics analysis. Front Genet. 2018;9:265. https://doi.org/10.3389/fgene.2018.00265.CrossRefPubMedPubMedCentral

28.

Zeng F, Fu J, Hu F, Tang Y, Fang X, Zeng F, et al. Identification of key pathways and genes in response to trastuzumab treatment in breast cancer using bioinformatics analysis. Oncotarget. 2018;9(63):32149–60. https://doi.org/10.18632/oncotarget.24605.CrossRefPubMedPubMedCentral

29.

Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007;7(9):659–72. https://doi.org/10.1038/nrc2193.CrossRefPubMed

30.

Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood, NJ). 2018;243(3):213–21.CrossRef

31.

Li G, Hu J, Hu G. Biomarker studies in early detection and prognosis of breast Cancer. Adv Exp Med Biol. 2017;1026:27–39. https://doi.org/10.1007/978-981-10-6020-5_2.CrossRefPubMed

32.

Pedersen MH, Hood BL, Ehmsen S, Beck HC, Conrads TP, Bak M, et al. CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients. Int J Cancer. 2019;144(3):631–40. https://doi.org/10.1002/ijc.31798.CrossRefPubMed

33.

Tang L, Chen Y, Tang X, Wei D, Xu X, Yan F. Long noncoding RNA DCST1-AS1 promotes cell proliferation and metastasis in triple-negative breast Cancer by forming a positive regulatory loop with miR-873-5p and MYC. J Cancer. 2020;11(2):311–23. https://doi.org/10.7150/jca.33982.CrossRefPubMedPubMedCentral

34.

Boac BM, Abbasi F, Ismail-Khan R, Xiong Y, Siddique A, Park H, et al. Expression of the BAD pathway is a marker of triple-negative status and poor outcome. Sci Rep. 2019;9(1):17496. https://doi.org/10.1038/s41598-019-53695-0.CrossRefPubMedPubMedCentral

35.

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51. https://doi.org/10.1002/pro.3715.CrossRefPubMedPubMedCentral

36.

Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–d551. https://doi.org/10.1093/nar/gkaa970.CrossRefPubMed

37.

Pathan M, Keerthikumar S, Chisanga D, Alessandro R, Ang CS, Askenase P, et al. A novel community driven software for functional enrichment analysis of extracellular vesicles data. J Extracellular Vesicles. 2017;6(1):1321455. https://doi.org/10.1080/20013078.2017.1321455.CrossRef

38.

Lin CY, Lee TL, Chiu YY, Lin YW, Lo YS, Lin CT, et al. Module organization and variance in protein-protein interaction networks. Sci Rep. 2015;5(1):9386. https://doi.org/10.1038/srep09386.CrossRefPubMedPubMedCentral

39.

Otasek D, Morris JH, Bouças J, Pico AR, Demchak B. Cytoscape automation: empowering workflow-based network analysis. Genome Biol. 2019;20(1):185. https://doi.org/10.1186/s13059-019-1758-4.CrossRefPubMedPubMedCentral

40.

Tang Y, Li M, Wang J, Pan Y, Wu FX. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Bio Systems. 2015;127:67–72. https://doi.org/10.1016/j.biosystems.2014.11.005.CrossRefPubMed

41.

Höppener DJ, Nierop PMH, van Amerongen MJ, Olthof PB, Galjart B, van Gulik TM, et al. The disease-free interval between resection of primary colorectal malignancy and the detection of hepatic metastases predicts disease recurrence but not overall survival. Ann Surg Oncol. 2019;26(9):2812–20. https://doi.org/10.1245/s10434-019-07481-x.CrossRefPubMedPubMedCentral

42.

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30. https://doi.org/10.1056/NEJMoa1406470.CrossRefPubMed

43.

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67. https://doi.org/10.1172/JCI45014.CrossRefPubMedPubMedCentral

44.

Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–98. https://doi.org/10.1158/1078-0432.CCR-14-0432.CrossRefPubMed

45.

Prasad S, Efird JT, James SE, Walker PR, Zagar TM, Biswas T. Failure patterns and survival outcomes in triple negative breast cancer (TNBC): a 15 year comparison of 448 non-Hispanic black and white women. SpringerPlus. 2016;5(1):756. https://doi.org/10.1186/s40064-016-2444-6.CrossRefPubMedPubMedCentral

46.

Battisti NML, Okonji D, Manickavasagar T, Mohammed K, Allen M, Ring A. Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience. Breast (Edinburgh, Scotland). 2018;40:60–6.CrossRef

47.

Wang X, Lu N, Niu B, Chen X, Xie J, Cheng N. Overexpression of Aurora-a enhances invasion and matrix metalloproteinase-2 expression in esophageal squamous cell carcinoma cells. Mol Cancer Res. 2012;10(5):588–96. https://doi.org/10.1158/1541-7786.MCR-11-0416.CrossRefPubMed

48.

Leontovich AA, Jalalirad M, Salisbury JL, Mills L, Haddox C, Schroeder M, et al. NOTCH3 expression is linked to breast cancer seeding and distant metastasis. Breast Cancer Res. 2018;20(1):105. https://doi.org/10.1186/s13058-018-1020-0.CrossRefPubMedPubMedCentral

49.

Seniski GG, Camargo AA, Ierardi DF, Ramos EA, Grochoski M, Ribeiro ES, et al. ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. BMC Cancer. 2009;9(1):80. https://doi.org/10.1186/1471-2407-9-80.CrossRefPubMedPubMedCentral

50.

Manica GC, Ribeiro CF, Oliveira MA, Pereira IT, Chequin A, Ramos EA, et al. Down regulation of ADAM33 as a predictive biomarker of aggressive breast Cancer. Sci Rep. 2017;7(1):44414. https://doi.org/10.1038/srep44414.CrossRefPubMedPubMedCentral

51.

Xu W, Wang Y, Wang Y, Lv S, Xu X, Dong X. Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer. Int J Mol Med. 2019;44(2):390–404. https://doi.org/10.3892/ijmm.2019.4239.CrossRefPubMedPubMedCentral

52.

Zhai X, Yang Z, Liu X, Dong Z, Zhou D. Identification of NUF2 and FAM83D as potential biomarkers in triple-negative breast cancer. PeerJ. 2020;8:e9975. https://doi.org/10.7717/peerj.9975.CrossRefPubMedPubMedCentral

53.

Chen C, Chen S, Pang L, Yan H, Luo M, Zhao Q, et al. Analysis of the expression of cell division cycle-associated genes and its prognostic significance in human lung carcinoma: a review of the literature databases. Biomed Res Int. 2020;2020:6412593.PubMedPubMedCentral

54.

Wu ZH, Fang M, Zhou Y. Comprehensive analysis of the expression and prognosis for CDCAs in head and neck squamous cell carcinoma. PLoS One. 2020;15(7):e0236678. https://doi.org/10.1371/journal.pone.0236678.CrossRefPubMedPubMedCentral

55.

Phan NN, Wang CY, Li KL, Chen CF, Chiao CC, Yu HG, et al. Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient. Oncotarget. 2018;9(6):6977–92. https://doi.org/10.18632/oncotarget.24059.CrossRefPubMedPubMedCentral

56.

Blanco G, Holli K, Heikkinen M, Kallioniemi OP, Taskinen P. Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer. 1990;62(1):142–6. https://doi.org/10.1038/bjc.1990.247.CrossRefPubMedPubMedCentral

57.

Cao Y, Zhang G, Bao H, Zhang S, Zhang J, Zhao Z, et al. Development of a dual-energy spectral CT based nomogram for the preoperative discrimination of mutated and wild-type KRAS in patients with colorectal cancer. Clin Imaging. 2021;69:205–12. https://doi.org/10.1016/j.clinimag.2020.08.023.CrossRefPubMed

58.

He S, Wang W, Wan Z, Shen H, Zhao Y, You Z, et al. FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway. Oncogenesis. 2021;10(1):6. https://doi.org/10.1038/s41389-020-00301-y.CrossRefPubMedPubMedCentral

59.

Cipriano R, Graham J, Miskimen KL, Bryson BL, Bruntz RC, Scott SA, et al. FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J Clin Invest. 2012;122(9):3197–210. https://doi.org/10.1172/JCI60517.CrossRefPubMedPubMedCentral

60.

Cipriano R, Miskimen KL, Bryson BL, Foy CR, Bartel CA, Jackson MW. FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies. Oncotarget. 2013;4(5):729–38. https://doi.org/10.18632/oncotarget.1027.CrossRefPubMedPubMedCentral

61.

Shen CQ, Yan TT, Liu W, Zhu XQ, Tian XL, Fu XL, et al. High expression of FAM83B predicts poor prognosis in patients with pancreatic ductal adenocarcinoma and correlates with cell cycle and cell proliferation. J Cancer. 2017;8(16):3154–65. https://doi.org/10.7150/jca.20086.CrossRefPubMedPubMedCentral

62.

Okabe N, Ezaki J, Yamaura T, Muto S, Osugi J, Tamura H, et al. FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma. Int J Oncol. 2015;46(3):999–1006. https://doi.org/10.3892/ijo.2015.2817.CrossRefPubMedPubMedCentral

63.

Le KN, Gibiansky L, Good J, Davancaze T, van Lookeren CM, Loyet KM, et al. A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy. J Pharmacol Exp Ther. 2015;355(2):288–96. https://doi.org/10.1124/jpet.115.227223.CrossRefPubMed

64.

Loveridge CJ, Slater S, Campbell KJ, Nam NA, Knight J, Ahmad I, et al. BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene. 2020;39(8):1797–806. https://doi.org/10.1038/s41388-019-1106-x.CrossRefPubMed

65.

Barnum SR, Ishii Y, Agrawal A, Volanakis JE. Production and interferon-gamma-mediated regulation of complement component C2 and factors B and D by the astroglioma cell line U105-MG. Biochem J. 1992;287(Pt 2):595–601.CrossRef

66.

Necchi A, Eigl BJ, Yang ES, Bae S, Chandrashekar D, Chen D, et al. Gene expression profiling of advanced penile squamous cell carcinoma receiving Cisplatin-based chemotherapy improves prognostication and identifies potential therapeutic targets. Eur Urol Focus. 2018;4(5):733–6. https://doi.org/10.1016/j.euf.2016.08.001.CrossRefPubMed

67.

Zhang K, Liu J, Li C, Peng X, Li H, Li Z. Identification and validation of potential target genes in papillary thyroid cancer. Eur J Pharmacol. 2019;843:217–25. https://doi.org/10.1016/j.ejphar.2018.11.026.CrossRefPubMed

68.

Lacher MD, Bauer G, Fury B, Graeve S, Fledderman EL, Petrie TD, et al. SV-BR-1-GM, a clinically effective GM-CSF-secreting breast Cancer cell line, expresses an immune signature and directly activates CD4(+) T lymphocytes. Front Immunol. 2018;9:776. https://doi.org/10.3389/fimmu.2018.00776.CrossRefPubMedPubMedCentral

69.

Cimino-Mathews A, Foote JB, Emens LA, et al. Oncology (Williston Park, NY). 2015;29(5):375–85.

70.

Yen MC, Huang YC, Kan JY, Kuo PL, Hou MF, Hsu YL. S100B expression in breast cancer as a predictive marker for cancer metastasis. Int J Oncol. 2018;52(2):433–40. https://doi.org/10.3892/ijo.2017.4226.CrossRefPubMed

71.

Galbiatti AL, Castro R, Caldas HC, Padovani JA Jr, Pavarino EC, Goloni-Bertollo EM. Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate. Tumour Biol. 2013;34(6):3765–71. https://doi.org/10.1007/s13277-013-0960-3.CrossRefPubMed

72.

Le K, Guo H, Zhang Q, Huang X, Xu M, Huang Z, et al. Gene and lncRNA co-expression network analysis reveals novel ceRNA network for triple-negative breast cancer. Sci Rep. 2019;9(1):15122. https://doi.org/10.1038/s41598-019-51626-7.CrossRefPubMedPubMedCentral

73.

Chen W, Liao L, Lai H, Yi X, Wang D. Identification of core biomarkers associated with pathogenesis and prognostic outcomes of laryngeal squamous-cell cancer using bioinformatics analysis. Eur Archiv Oto-rhino-laryngology. 2020;277(5):1397–408.CrossRef

74.

Shi T, Jiang R, Wang P, Xu Y, Yin S, Cheng X, et al. Significant association of the EXO1 rs851797 polymorphism with clinical outcome of ovarian cancer. OncoTargets Ther. 2017;10:4841–51. https://doi.org/10.2147/OTT.S141668.CrossRef

75.

Zhang M, Zhao D, Yan C, Zhang L, Liang C. Associations between nine polymorphisms in EXO1 and Cancer susceptibility: a systematic review and meta-analysis of 39 case-control studies. Sci Rep. 2016;6(1):29270. https://doi.org/10.1038/srep29270.CrossRefPubMedPubMedCentral

76.

Qi L, Zhou B, Chen J, Hu W, Bai R, Ye C, et al. Significant prognostic values of differentially expressed-aberrantly methylated hub genes in breast cancer. J Cancer. 2019;10(26):6618–34. https://doi.org/10.7150/jca.33433.CrossRefPubMedPubMedCentral

77.

Franzese C, Di Brina L, D'Agostino G, Franceschini D, Comito T, De Rose F, et al. Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis. J Cancer Res Clin Oncol. 2019;145(10):2469–79. https://doi.org/10.1007/s00432-019-03007-w.CrossRefPubMed

78.

Jiang Y, Zhang M, Qian Y, Xu E, Zhang J, Chen X. Rbm24, an RNA-binding protein and a target of p53, regulates p21 expression via mRNA stability. J Biol Chem. 2014;289(6):3164–75. https://doi.org/10.1074/jbc.M113.524413.CrossRefPubMed

79.

Xu E, Zhang J, Zhang M, Jiang Y, Cho SJ, Chen X. RNA-binding protein RBM24 regulates p63 expression via mRNA stability. Mol Cancer Res. 2014;12(3):359–69. https://doi.org/10.1158/1541-7786.MCR-13-0526.CrossRefPubMed

Title: Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers
Authors: Yiduo Liu
Linxin Teng
Shiyi Fu
Guiyang Wang
Zhengjun Li
Chao Ding
Haodi Wang
Lei Bi
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Targeted Therapy
Biomarkers
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08318-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias

Attention to principles of exercise training: an updated systematic review of randomized controlled trials in cancers other than breast and prostate

A novel ferroptosis-related 12-gene signature predicts clinical prognosis and reveals immune relevancy in clear cell renal cell carcinoma

Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews

Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients

Use of rehabilitation pathways in women with breast cancer in the first 12 months of the disease: a retrospective study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer